Satoshi Itano

Kurume, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Innovation of a Repeatable Microcatheter-accessible Port (ReMAP): Initial Clinical Results Evaluating Feasibility in the Treatment of Hepatocellular Carcinoma.

Innovation of a Repeatable Microcatheter-accessible Port (ReMAP): Initial Clinical Results Evaluating Feasibility in the Treatment of Hepatocellular Carcinoma.

Journal: Interventional radiology (Higashimatsuyama-shi (Japan)

Published: September 02, 2025

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 27, 2025

Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: A retrospective cohort study.

Hepatic arterial infusion is effective in patients with unresectable colorectal liver metastases refractory to standard systemic chemotherapy: A retrospective cohort study.

Journal: PloS one

Published: May 23, 2025

Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.

Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 04, 2024

Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.

Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.

Journal: PloS one

Published: July 16, 2024

Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.

Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.

Journal: Oncology letters

Published: March 01, 2024

Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study.

Metabolic management after sustained virologic response in elderly patients with hepatitis C virus: A multicenter study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: July 20, 2023

The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.

Journal: Cancer medicine

Published: February 15, 2023

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.

Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study.

Journal: Cancers

Published: July 21, 2022

Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.

Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma.

Journal: Scientific reports

Published: July 05, 2022

Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study.

Efficacy and Safety of Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma and Child-Pugh Class B: A Retrospective Cohort Study.

Journal: Oncology

Published: December 20, 2021

First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.

First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.

Journal: Cancer medicine

Published: September 09, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026